Paradigm Biopharmaceuticals Ltd
ASX:PAR
Paradigm Biopharmaceuticals Ltd
Revenue
Paradigm Biopharmaceuticals Ltd
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Paradigm Biopharmaceuticals Ltd
ASX:PAR
|
Revenue
AU$8.7m
|
CAGR 3-Years
29%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
Immutep Ltd
ASX:IMM
|
Revenue
AU$256.6k
|
CAGR 3-Years
-61%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
-24%
|
|
Mesoblast Ltd
ASX:MSB
|
Revenue
$7.5m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
CSL Ltd
ASX:CSL
|
Revenue
$14.2B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
10%
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Revenue
AU$87.3m
|
CAGR 3-Years
31%
|
CAGR 5-Years
25%
|
CAGR 10-Years
42%
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Revenue
AU$502.5m
|
CAGR 3-Years
359%
|
CAGR 5-Years
381%
|
CAGR 10-Years
N/A
|
See Also
What is Paradigm Biopharmaceuticals Ltd's Revenue?
Revenue
8.7m
AUD
Based on the financial report for Dec 31, 2023, Paradigm Biopharmaceuticals Ltd's Revenue amounts to 8.7m AUD.
What is Paradigm Biopharmaceuticals Ltd's Revenue growth rate?
Revenue CAGR 5Y
26%
Over the last year, the Revenue growth was -3%. The average annual Revenue growth rates for Paradigm Biopharmaceuticals Ltd have been 29% over the past three years , 26% over the past five years .